New Therapeutics Approaches in the Autoimmune Field
Author(s):
Giada Rossi1,2, Sharon Failla3
and Giorgia Isinelli4*
The immune system is critical in defending the body against pathogens and foreign substances through innate and adaptive responses. However, dysregulation of these immune reactions can result in autoimmune diseases, where the immune system erroneously targets self-tissues. Autoimmunity is influenced by multiple factors, with specific susceptibility genes and environmental triggers contributing to disease onset and progression. Traditional treatments for autoimmune diseases, such as immunosuppressants and biologic agents, aim to manage symptoms but often fail to address the root cause of immune tolerance breakdown, leading to limited efficacy and adverse effects. In recent years, nanoparticles have emerged as potential immunomodulatory agents, offering novel therapeutic strategies targeting key immune components. Cationic nanoparticles, particularly poly(amidoamine) (PAMAM) dendrimers, can interact with extracellular nucleic acids, modulate macrophage polarization, and induce immune tolerance, thereby reducing inflammation and autoimmune activity. These nanoparticles hold promise in diseases such as rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. Despite their potential, challenges remain in optimizing nanoparticle formulations, understanding their long-term effects, and ensuring clinical safety. Future research focusing on improving targeting efficiency, reducing toxicity, and validating clinical outcomes will translate these innovative therapies into effective treatments for autoimmune diseases.
